CL2004000391A1 - Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina. - Google Patents

Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina.

Info

Publication number: CL2004000391A1
Authority: CL; Chile
Prior art keywords: compounds; dislipidemia; oxazol; diabetes; pharmaceutical composition
Prior art date: 2003-02-27

Application number

CL200400391A

Other languages

English (en)

Inventor

Kirk Glombik Heiner Fa Gretzke

Original Assignee

Sanofi Aventis Deutschland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-02-27

Filing date

2004-02-27

Publication date

2005-01-07

2004-02-27 Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland

2005-01-07 Publication of CL2004000391A1 publication Critical patent/CL2004000391A1/es

Links

150000001875 compounds Chemical class 0.000 title 2
206010022489 Insulin Resistance Diseases 0.000 title 1
ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 title 1
206010012601 diabetes mellitus Diseases 0.000 title 1
208000030159 metabolic disease Diseases 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
208000001072 type 2 diabetes mellitus Diseases 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Hematology (AREA)
Endocrinology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Plural Heterocyclic Compounds (AREA)
Pyrrole Compounds (AREA)

CL200400391A 2003-02-27 2004-02-27 Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina. CL2004000391A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10308355A DE10308355A1 (de)	2003-02-27	2003-02-27	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel

Publications (1)

Publication Number	Publication Date
CL2004000391A1 true CL2004000391A1 (es)	2005-01-07

Family

ID=32920629

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CL200400392A CL2004000392A1 (es)	2003-02-27	2004-02-27	Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra
CL200400391A CL2004000391A1 (es)	2003-02-27	2004-02-27	Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CL200400392A CL2004000392A1 (es)	2003-02-27	2004-02-27	Compuestos derivados de 1,3-oxazol 2,4,5-trisustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion farmaceutica; y uso de los compuestos para tratar resistencia a la insulina, diabetes mellitus, dislipidemia, entre otra

Country Status (34)

Country	Link
US (5)	US7365084B2 (es)
EP (3)	EP1599453B1 (es)
JP (3)	JP2006519193A (es)
KR (3)	KR20050106462A (es)
CN (3)	CN100398526C (es)
AR (3)	AR043432A1 (es)
AT (3)	ATE435217T1 (es)
AU (3)	AU2004215672B2 (es)
BR (3)	BRPI0407758A (es)
CA (3)	CA2517381A1 (es)
CL (2)	CL2004000392A1 (es)
CO (2)	CO5690578A2 (es)
DE (4)	DE10308355A1 (es)
DK (3)	DK1599453T3 (es)
EC (2)	ECSP055986A (es)
ES (3)	ES2326418T3 (es)
HR (3)	HRP20050744A2 (es)
IL (2)	IL170316A (es)
MA (3)	MA27736A1 (es)
MX (3)	MXPA05008988A (es)
NO (3)	NO20054398L (es)
OA (2)	OA13035A (es)
PA (1)	PA8596801A1 (es)
PE (3)	PE20050292A1 (es)
PL (3)	PL378437A1 (es)
PT (3)	PT1599453E (es)
RS (1)	RS20050594A (es)
RU (3)	RU2005130002A (es)
SA (1)	SA04250153A (es)
TN (2)	TNSN05206A1 (es)
TW (3)	TW200510352A (es)
UY (2)	UY28209A1 (es)
WO (3)	WO2004076428A1 (es)
ZA (2)	ZA200505765B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6262118B1 (en) *	1999-06-04	2001-07-17	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes and hyperlipidemia
US7576131B2 (en) *	1999-06-04	2009-08-18	Metabolex, Inc.	Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia
US7399777B2 (en) *	2001-08-31	2008-07-15	Sanofi-Aventis Deutschland Gmbh	Diarylcycloalkyl derivatives, processes for their preparation and their use as pharmceuticals
DE10308353A1 (de) *	2003-02-27	2004-12-02	Aventis Pharma Deutschland Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004038403B4 (de) *	2004-08-07	2006-08-31	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung der enantiomeren Formen von cis-konfigurierten 3-Hydroxycyclohexancarbonsäure-Derivaten
DE102004039509B4 (de)	2004-08-14	2006-09-21	Sanofi-Aventis Deutschland Gmbh	Aryl-cycloalkyl substituierte Alkansäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039532B4 (de) *	2004-08-14	2006-09-21	Sanofi-Aventis Deutschland Gmbh	Cyclohexyl-methyloxy substituierte Essigsäurederivate, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004039533B4 (de)	2004-08-14	2006-09-28	Sanofi-Aventis Deutschland Gmbh	Essigsäurederivate mit Cyclohexylmethoxy-Substituenten, Verfahren zu ihrer Herstellung und ihre Anwendung als Arzneimittel
DE102004060227B3 (de)	2004-12-15	2006-07-20	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von Oxazolen durch Kondensation von aromatischen Aldehyden mit α-Ketoximen zu N-Oxiden und nachfolgende Reaktion mit aktivierten Säurederivaten
GT200600218A (es) *	2005-06-10	2007-03-28		Formulación y proceso de compresión directa
JP2009509988A (ja)	2005-09-29	2009-03-12	サノフィ−アベンティス	フェニル−及びピリジニル−１，２，４−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
AU2006347121B2 (en)	2006-08-10	2013-06-06	Acacia-No-Ki Co., Ltd.	Hypoglycemic composition containing component originating in the bark of tree belonging to the genus Acacia
CN105732376A (zh)	2007-08-16	2016-07-06	索尔维公司	制备4-氟取代的3-氧代-烷酸酯的方法
TWI476187B (zh) *	2008-02-29	2015-03-11	Nissan Chemical Ind Ltd	Thiophene compounds and intermediates thereof
US7615661B2 (en) *	2008-03-12	2009-11-10	International Flavors & Fragrances Inc.	Thioester compounds and their use in fragrance or flavor applications
CN121742154A (zh)	2017-12-13	2026-03-27	佳能株式会社	盒与图像形成装置
CN109810071B (zh) *	2019-03-28	2023-04-21	中国科学院成都生物研究所	一种miRNA生物合成抑制剂

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2663336B1 (fr)	1990-06-18	1992-09-04	Adir	Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2663464B1 (fr)	1990-06-19	1992-09-11	Commissariat Energie Atomique	Circuit integre en technologie silicium sur isolant comportant un transistor a effet de champ et son procede de fabrication.
IL108634A0 (en)	1993-02-15	1994-05-30	Wellcome Found	Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
IL108633A (en)	1993-02-15	1998-07-15	Wellcome Found	History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
JP3144624B2 (ja)	1995-06-02	2001-03-12	杏林製薬株式会社	Ｎ−ベンジルジオキソチアゾリジルベンズアミド誘導体及びその製造法
AU727775B2 (en)	1996-01-17	2000-12-21	Novo Nordisk A/S	Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
IL128332A0 (en)	1996-08-30	2000-01-31	Novo Nordisk As	GLP-1 derivatives
TW492957B (en)	1996-11-07	2002-07-01	Novartis Ag	N-substituted 2-cyanopyrrolidnes
IL127296A (en)	1996-12-31	2003-01-12	Reddy Research Foundation	Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
DE19726167B4 (de) *	1997-06-20	2008-01-24	Sanofi-Aventis Deutschland Gmbh	Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
PL338013A1 (en)	1997-07-16	2000-09-25	Novo Nordisk As	Derivatives of condensed 1,2,4-thiadiazine, their production and application
CO4970713A1 (es)	1997-09-19	2000-11-07	Sanofi Synthelabo	Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
ATE451346T1 (de) *	1998-03-10	2009-12-15	Ono Pharmaceutical Co	Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
DE19823831A1 (de)	1998-05-28	1999-12-02	Probiodrug Ges Fuer Arzneim	Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
MA26634A1 (fr)	1998-06-04	2004-12-20	Astra Ab	Nouveaux derives de l'acide 3-aryl propionique et analogues
SE9801992D0 (sv)	1998-06-04	1998-06-04	Astra Ab	New 3-aryl-2-hydroxypropionic acid derivative I
US6221897B1 (en) *	1998-06-10	2001-04-24	Aventis Pharma Deutschland Gmbh	Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19828113A1 (de)	1998-06-24	2000-01-05	Probiodrug Ges Fuer Arzneim	Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV
DE19828114A1 (de)	1998-06-24	2000-01-27	Probiodrug Ges Fuer Arzneim	Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
US6664281B1 (en) *	1998-08-27	2003-12-16	Ono Pharmaceutical Co., Ltd.	Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19845405C2 (de)	1998-10-02	2000-07-13	Aventis Pharma Gmbh	Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en)	1999-01-08	1999-02-24	Alizyme Therapeutics Ltd	Inhibitors
DE19916108C1 (de) *	1999-04-09	2001-01-11	Aventis Pharma Gmbh	Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung
JP2002542245A (ja)	1999-04-16	2002-12-10	ノボノルディスクアクティーゼルスカブ	置換イミダゾール、それらの製造および使用
US6908926B1 (en)	1999-04-16	2005-06-21	Novo Nordisk A/S	Substituted imidazoles, their preparation and use
NZ515086A (en)	1999-04-28	2003-10-31	Aventis Pharma Gmbh	Di-aryl acid derivatives as PPAR receptor ligands
EP1177176B1 (en) *	1999-04-28	2006-04-19	Aventis Pharma Deutschland GmbH	Tri-aryl acid derivatives as ppar receptor ligands
WO2000066585A1 (en)	1999-04-30	2000-11-09	Neurogen Corporation	9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
GB9911863D0 (en)	1999-05-21	1999-07-21	Knoll Ag	Therapeutic agents
DE60029446T2 (de)	1999-06-18	2007-02-08	Merck & Co., Inc.	Arylthiazolidindione und aryloxazolidindion-derivate
JP2003504082A (ja)	1999-07-09	2003-02-04	コヘージョンテクノロジーズ，インコーポレイテッド	エカリンポリペプチド、エカリンをコードするポリヌクレオチド、及びその利用のための方法
BR0012752A (pt)	1999-07-29	2002-04-02	Lilly Co Eli	Benzofuril piperazinas e benzofuril homopiperazinas: agonistas de serotonina
HUP0202472A3 (en) *	1999-09-01	2005-03-29	Aventis Pharma Gmbh	Sulfonyl carboxiamide derivatives, method for their production and their use as medicaments
TWI302149B (en)	1999-09-22	2008-10-21	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
DK1237855T3 (da)	1999-12-03	2004-06-14	Astrazeneca Ab	Krystallinsk form af (S)-2-ethoxy-3-[4-(2-(4-methansulfonyloxyphenyl)ethoxy)phenyl]propansyre
SE9904413D0 (sv)	1999-12-03	1999-12-03	Astra Ab	Comminuted form
HU229042B1 (en)	2000-03-31	2013-07-29	Prosidion Ltd	Method for the improvement of islet signaling in diabetes mellitus and for its prevention
MXPA02010545A (es)	2000-04-25	2004-05-14	Kyorin Seiyaku Kk	Cristal estable novedoso de derivado de tiazolidinediona y proceso para producir el mismo.
AU5257401A (en)	2000-04-28	2001-11-12	Asahi Chemical Ind	Novel bicyclic compounds
DE60115227T2 (de)	2000-05-11	2006-08-24	Bristol-Myers Squibb Co.	Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
EP1289526A4 (en)	2000-05-30	2005-03-16	Merck & Co Inc	MELANOCORTIN RECEPTOR AGONISTS
TR200401029T4 (tr)	2000-06-09	2004-06-21	Aventis Pharma Deutschland Gmbh	Asilfenil-üre türevleri, imalat yöntemleri ve ilaç maddesi olarak kullanımları
DE10038709A1 (de)	2000-08-09	2002-02-28	Aventis Pharma Gmbh	Substituierte und unsubstituierte Benzooxathiazole sowie daraus abgeleitete Verbindungen
EP1182251A1 (en) *	2000-08-11	2002-02-27	Yissum Research Development Company of the Hebrew University of Jerusalem	Methods for identifying compounds that inhibit ubiquitin-mediated proteolysis of IkB
DE60129712T2 (de)	2000-08-23	2008-07-03	Eli Lilly And Co., Indianapolis	Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten
HUP0300857A3 (en) *	2000-08-23	2007-03-28	Lilly Co Eli	Oxazolyl-arylpropionic acid derivatives and their use as ppar agonists
TWI243162B (en)	2000-11-10	2005-11-11	Taisho Pharmaceutical Co Ltd	Cyanopyrrolidine derivatives
WO2002046146A1 (fr)	2000-12-05	2002-06-13	Kyorin Pharmaceutical Co., Ltd.	Derives d'acide carboxylique substitues
GB0031103D0 (en) *	2000-12-20	2001-01-31	Glaxo Group Ltd	Chemical compounds
HRP20030498A2 (en)	2000-12-21	2005-04-30	Aventis Pharma Deutschland Gmbh	Novel 1,2-diphenzylazetidinones, method for producing the same, medicaments containing said compounds, and the use thereof for treating disorders of the lipid metabolism
ES2291378T3 (es) *	2000-12-25	2008-03-01	Ono Pharmaceutical Co., Ltd.	Compuestos derivados de dihidronaftaleno y medicamentos que utilizan estos compuestos como ingrediente activo.
EP1360172A1 (en)	2001-02-15	2003-11-12	Pfizer Products Inc.	Ppar agonists
PE20021091A1 (es)	2001-05-25	2003-02-04	Aventis Pharma Gmbh	Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
EA200400011A1 (ru) *	2001-06-07	2004-06-24	Эли Лилли Энд Компани	Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar)
DE10154689A1 (de)	2001-11-09	2003-05-22	Probiodrug Ag	Substituierte Aminoketonverbindungen
WO2003005025A1 (en)	2001-07-03	2003-01-16	Biovitrum Ab	Methods for identifying compounds modulating the activity of ppar-gamma
FR2827859B1 (fr)	2001-07-30	2005-09-23	Lipha	Derives 4-(arylthio) - ou 4-(heteroarylthio) -butyrique dans la preparation de medicaments destines au traitement du diabete
HRP20040199A2 (en)	2001-08-31	2005-04-30	Aventis Pharma Deutschland Gmbh	Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
AU2003207432A1 (en)	2002-02-05	2003-09-02	Eli Lilly And Company	Urea linker derivatives for use as ppar modulators
DE10215908B4 (de)	2002-04-11	2005-08-18	Aventis Pharma Deutschland Gmbh	Acyl-3-carboxyphenyl-harnstoffderivate und deren Verwendung als Arzneimittel
DE10215907A1 (de)	2002-04-11	2003-11-06	Aventis Pharma Gmbh	Acyl-4-carboxyphenyl-harnstoffderivate, Verfahren zu deren Herstellung und deren Verwendung
DE10225635C1 (de)	2002-06-07	2003-12-24	Aventis Pharma Gmbh	N-Benzoylureido-Zimtsäurederivate, Verfahren zu deren Herstellung und deren Verwendung
AU2003259131A1 (en)	2002-07-09	2004-01-23	Bristol-Myers Squibb Company	Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
US7148246B2 (en) *	2003-02-27	2006-12-12	Sanofi-Aventis Deutschland Gmbh	Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals

2003
- 2003-02-27 DE DE10308355A patent/DE10308355A1/de not_active Withdrawn
2004
- 2004-02-19 KR KR1020057016023A patent/KR20050106462A/ko not_active Ceased
- 2004-02-19 CN CNB2004800054985A patent/CN100398526C/zh not_active Expired - Fee Related
- 2004-02-19 RU RU2005130002/04A patent/RU2005130002A/ru not_active Application Discontinuation
- 2004-02-19 AT AT04712503T patent/ATE435217T1/de not_active IP Right Cessation
- 2004-02-19 PT PT04712494T patent/PT1599453E/pt unknown
- 2004-02-19 RU RU2005129992/04A patent/RU2005129992A/ru not_active Application Discontinuation
- 2004-02-19 KR KR1020057015851A patent/KR20050105492A/ko not_active Ceased
- 2004-02-19 WO PCT/EP2004/001586 patent/WO2004076428A1/de not_active Ceased
- 2004-02-19 BR BRPI0407758-0A patent/BRPI0407758A/pt not_active IP Right Cessation
- 2004-02-19 OA OA1200500248A patent/OA13035A/en unknown
- 2004-02-19 AU AU2004215672A patent/AU2004215672B2/en not_active Ceased
- 2004-02-19 HR HR20050744A patent/HRP20050744A2/xx not_active Application Discontinuation
- 2004-02-19 WO PCT/EP2004/001578 patent/WO2004076426A1/de not_active Ceased
- 2004-02-19 AU AU2004215677A patent/AU2004215677B2/en not_active Ceased
- 2004-02-19 MX MXPA05008988A patent/MXPA05008988A/es active IP Right Grant
- 2004-02-19 RS YUP-2005/0594A patent/RS20050594A/sr unknown
- 2004-02-19 AU AU2004215673A patent/AU2004215673B2/en not_active Ceased
- 2004-02-19 BR BRPI0407814-4A patent/BRPI0407814A/pt not_active IP Right Cessation
- 2004-02-19 HR HR20050743A patent/HRP20050743A2/xx not_active Application Discontinuation
- 2004-02-19 DK DK04712494T patent/DK1599453T3/da active
- 2004-02-19 ES ES04712494T patent/ES2326418T3/es not_active Expired - Lifetime
- 2004-02-19 PT PT04712490T patent/PT1599452E/pt unknown
- 2004-02-19 BR BRPI0407907-8A patent/BRPI0407907A/pt not_active IP Right Cessation
- 2004-02-19 JP JP2006501885A patent/JP2006519193A/ja active Pending
- 2004-02-19 AT AT04712494T patent/ATE430738T1/de not_active IP Right Cessation
- 2004-02-19 JP JP2006501892A patent/JP2006519199A/ja active Pending
- 2004-02-19 CN CNB2004800054769A patent/CN100439347C/zh not_active Expired - Fee Related
- 2004-02-19 PL PL378437A patent/PL378437A1/pl not_active Application Discontinuation
- 2004-02-19 MX MXPA05008995A patent/MXPA05008995A/es active IP Right Grant
- 2004-02-19 DE DE502004009690T patent/DE502004009690D1/de not_active Expired - Lifetime
- 2004-02-19 MX MXPA05008951A patent/MXPA05008951A/es active IP Right Grant
- 2004-02-19 CA CA002517381A patent/CA2517381A1/en not_active Abandoned
- 2004-02-19 ES ES04712490T patent/ES2287700T3/es not_active Expired - Lifetime
- 2004-02-19 AT AT04712490T patent/ATE365159T1/de not_active IP Right Cessation
- 2004-02-19 CA CA002517386A patent/CA2517386A1/en not_active Abandoned
- 2004-02-19 DK DK04712490T patent/DK1599452T3/da active
- 2004-02-19 CA CA002516620A patent/CA2516620A1/en not_active Abandoned
- 2004-02-19 EP EP04712494A patent/EP1599453B1/de not_active Expired - Lifetime
- 2004-02-19 PT PT04712503T patent/PT1599455E/pt unknown
- 2004-02-19 OA OA1200500247A patent/OA13034A/en unknown
- 2004-02-19 EP EP04712490A patent/EP1599452B1/de not_active Expired - Lifetime
- 2004-02-19 PL PL378130A patent/PL378130A1/pl not_active Application Discontinuation
- 2004-02-19 DE DE502004009453T patent/DE502004009453D1/de not_active Expired - Lifetime
- 2004-02-19 JP JP2006501886A patent/JP2006519194A/ja active Pending
- 2004-02-19 KR KR1020057015995A patent/KR20050106461A/ko not_active Ceased
- 2004-02-19 EP EP04712503A patent/EP1599455B1/de not_active Expired - Lifetime
- 2004-02-19 WO PCT/EP2004/001579 patent/WO2004076427A1/de not_active Ceased
- 2004-02-19 PL PL377735A patent/PL377735A1/pl not_active Application Discontinuation
- 2004-02-19 DK DK04712503T patent/DK1599455T3/da active
- 2004-02-19 RU RU2005129995/04A patent/RU2005129995A/ru not_active Application Discontinuation
- 2004-02-19 ES ES04712503T patent/ES2329366T3/es not_active Expired - Lifetime
- 2004-02-19 HR HR20050742A patent/HRP20050742A2/xx not_active Application Discontinuation
- 2004-02-19 CN CNB2004800054379A patent/CN100439345C/zh not_active Expired - Fee Related
- 2004-02-19 DE DE502004004139T patent/DE502004004139D1/de not_active Expired - Lifetime
- 2004-02-25 TW TW093104705A patent/TW200510352A/zh unknown
- 2004-02-25 TW TW093104704A patent/TW200500349A/zh unknown
- 2004-02-25 TW TW093104697A patent/TW200508210A/zh unknown
- 2004-02-27 US US10/788,997 patent/US7365084B2/en not_active Expired - Fee Related
- 2004-02-27 CL CL200400392A patent/CL2004000392A1/es unknown
- 2004-02-27 AR ARP040100635A patent/AR043432A1/es not_active Application Discontinuation
- 2004-02-27 UY UY28209A patent/UY28209A1/es unknown
- 2004-02-27 US US10/789,017 patent/US7335671B2/en not_active Expired - Lifetime
- 2004-02-27 PE PE2004000203A patent/PE20050292A1/es not_active Application Discontinuation
- 2004-02-27 AR ARP040100629A patent/AR043427A1/es not_active Application Discontinuation
- 2004-02-27 AR ARP040100636A patent/AR043433A1/es not_active Application Discontinuation
- 2004-02-27 CL CL200400391A patent/CL2004000391A1/es unknown
- 2004-02-27 PA PA20048596801A patent/PA8596801A1/es unknown
- 2004-02-27 UY UY28210A patent/UY28210A1/es unknown
- 2004-02-27 US US10/788,996 patent/US7259177B2/en not_active Expired - Lifetime
- 2004-02-27 PE PE2004000205A patent/PE20050293A1/es not_active Application Discontinuation
- 2004-02-27 PE PE2004000206A patent/PE20040959A1/es not_active Application Discontinuation
- 2004-06-09 SA SA04250153A patent/SA04250153A/ar unknown
2005
- 2005-07-19 ZA ZA200505765A patent/ZA200505765B/en unknown
- 2005-07-19 ZA ZA200505768A patent/ZA200505768B/en unknown
- 2005-08-16 IL IL170316A patent/IL170316A/en not_active IP Right Cessation
- 2005-08-16 IL IL170314A patent/IL170314A/en not_active IP Right Cessation
- 2005-08-26 EC EC2005005986A patent/ECSP055986A/es unknown
- 2005-08-26 MA MA28459A patent/MA27736A1/fr unknown
- 2005-08-26 CO CO05085499A patent/CO5690578A2/es not_active Application Discontinuation
- 2005-08-26 MA MA28460A patent/MA27737A1/fr unknown
- 2005-08-26 TN TNP2005000206A patent/TNSN05206A1/en unknown
- 2005-08-26 TN TNP2005000204A patent/TNSN05204A1/en unknown
- 2005-08-26 EC EC2005005985A patent/ECSP055985A/es unknown
- 2005-08-26 CO CO05085508A patent/CO5690580A2/es not_active Application Discontinuation
- 2005-08-26 MA MA28465A patent/MA27742A1/fr unknown
- 2005-09-22 NO NO20054398A patent/NO20054398L/no unknown
- 2005-09-22 NO NO20054408A patent/NO20054408L/no unknown
- 2005-09-22 NO NO20054396A patent/NO20054396L/no unknown
2007
- 2007-08-16 US US11/839,950 patent/US20080015238A1/en not_active Abandoned
2008
- 2008-01-14 US US12/013,806 patent/US7872034B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1599453A1 (de)	2005-11-30
EP1599455B1 (de)	2009-07-01
RU2005129995A (ru)	2006-01-27
AU2004215673A1 (en)	2004-09-10
EP1599452A1 (de)	2005-11-30
MXPA05008951A (es)	2005-11-04
US20050215596A1 (en)	2005-09-29
MA27736A1 (fr)	2006-02-01
NO20054396D0 (no)	2005-09-22
JP2006519199A (ja)	2006-08-24
DK1599452T3 (da)	2007-10-01
US7335671B2 (en)	2008-02-26
EP1599455A1 (de)	2005-11-30
EP1599452B1 (de)	2007-06-20
WO2004076426A1 (de)	2004-09-10
ZA200505768B (en)	2005-11-23
UY28210A1 (es)	2004-09-30
US20040209920A1 (en)	2004-10-21
PE20050293A1 (es)	2005-05-24
UY28209A1 (es)	2004-09-30
RU2005129992A (ru)	2006-02-10
CN100398526C (zh)	2008-07-02
OA13034A (en)	2006-11-10
JP2006519193A (ja)	2006-08-24
PT1599455E (pt)	2009-09-29
TW200500349A (en)	2005-01-01
EP1599453B1 (de)	2009-05-06
US7365084B2 (en)	2008-04-29
DE10308355A1 (de)	2004-12-23
IL170314A (en)	2010-11-30
BRPI0407814A (pt)	2006-02-14
DK1599453T3 (da)	2009-08-24
CO5690580A2 (es)	2006-10-31
TNSN05206A1 (en)	2007-06-11
PT1599452E (pt)	2007-09-12
ES2329366T3 (es)	2009-11-25
PL378130A1 (pl)	2006-03-06
ATE365159T1 (de)	2007-07-15
ECSP055985A (es)	2006-01-16
AU2004215677B2 (en)	2010-01-07
RU2005130002A (ru)	2006-01-27
AU2004215672A1 (en)	2004-09-10
HRP20050744A2 (en)	2006-09-30
BRPI0407907A (pt)	2006-02-14
US7872034B2 (en)	2011-01-18
US20080167354A1 (en)	2008-07-10
NO20054396L (no)	2005-11-11
CN100439347C (zh)	2008-12-03
WO2004076428A1 (de)	2004-09-10
US20080015238A1 (en)	2008-01-17
PL378437A1 (pl)	2006-04-03
DE502004004139D1 (de)	2007-08-02
DK1599455T3 (da)	2009-11-09
OA13035A (en)	2006-11-10
AR043427A1 (es)	2005-07-27
US20050101637A1 (en)	2005-05-12
KR20050105492A (ko)	2005-11-04
TW200508210A (en)	2005-03-01
CN1753879A (zh)	2006-03-29
ECSP055986A (es)	2006-01-16
PT1599453E (pt)	2009-07-14
CL2004000392A1 (es)	2005-04-22
NO20054398L (no)	2005-11-02
TNSN05204A1 (en)	2007-06-11
MXPA05008995A (es)	2005-10-18
AU2004215672B2 (en)	2010-01-07
ATE430738T1 (de)	2009-05-15
AU2004215673B2 (en)	2009-10-01
MXPA05008988A (es)	2005-10-18
PE20040959A1 (es)	2005-01-17
CA2516620A1 (en)	2004-09-10
DE502004009453D1 (de)	2009-06-18
DE502004009690D1 (de)	2009-08-13
TW200510352A (en)	2005-03-16
JP2006519194A (ja)	2006-08-24
PL377735A1 (pl)	2006-02-20
AR043433A1 (es)	2005-07-27
ES2326418T3 (es)	2009-10-09
CA2517386A1 (en)	2004-09-10
NO20054398D0 (no)	2005-09-22
CN100439345C (zh)	2008-12-03
SA04250153A (ar)	2005-12-03
MA27742A1 (fr)	2006-02-01
ZA200505765B (en)	2006-05-31
NO20054408L (no)	2005-11-23
PA8596801A1 (es)	2004-09-16
CO5690578A2 (es)	2006-10-31
PE20050292A1 (es)	2005-05-24
KR20050106461A (ko)	2005-11-09
HRP20050743A2 (en)	2006-08-31
IL170316A (en)	2010-11-30
AR043432A1 (es)	2005-07-27
RS20050594A (sr)	2007-12-31
CN1756748A (zh)	2006-04-05
MA27737A1 (fr)	2006-02-01
NO20054408D0 (no)	2005-09-22
KR20050106462A (ko)	2005-11-09
AU2004215677A1 (en)	2004-09-10
CA2517381A1 (en)	2004-09-10
ATE435217T1 (de)	2009-07-15
BRPI0407758A (pt)	2006-02-14
CN1753881A (zh)	2006-03-29
US7259177B2 (en)	2007-08-21
HRP20050742A2 (en)	2006-09-30
ES2287700T3 (es)	2007-12-16
WO2004076427A1 (de)	2004-09-10

Publication	Publication Date	Title
CL2004000391A1 (es)	2005-01-07	Compuestos derivados de 1,3-oxazol; composicion farmaceutica; y uso de los compuestos para tratar trastornos metabolicos, tales como diabetes, dislipidemia, resistencia a la insulina.
CL2007003440A1 (es)	2008-04-04	Compuestos derivados de azacicloalcanos, inhibidores de estearoil-coenzima a delta-9 desaturasa; composicion farmaceutica; y uso para el tratamiento de enfermedades tales como diabetes tipo 2, resistencia a la insulina, trastornos de lipidos, obesida
CR8642A (es)	2008-11-28	Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
CL2004001069A1 (es)	2005-04-01	Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
BRPI0311275A2 (pt)	2016-06-28	"composições de fenofibrato estáveis para administração oral, bem como uso das mesmas"
CL2007001918A1 (es)	2008-03-28	Compuestos derivados heteroarilos sustituidos; metodo para la preparacion de los compuestos; composicion farmaceutica; y uso para el tratamiento del dolor, depresion, enfermedad de alzheimer e hipertension entre otras.
CL2011000144A1 (es)	2011-09-23	Compuestos derivados de benzo (1,4) dioxin-2-ilmetil-sulfamida; composiciones farmaceuticas que los contienen; proceso para prepararlos y uso en el tratamiento de la ansiedad, epilepsia, dolor, abuso de sustancias, trastornos relacionados, entre otros.
BRPI0607762B8 (pt)	2021-05-25	análogos de glp-1, composição farmacêutica contendo os mesmos e uso de um composto
CL2007003262A1 (es)	2008-05-30	Compuestos derivados de 1,4-benzotiepina-1,1-dioxido; composicion farmaceutica; y su uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del snc, entre otras enfermedades.
PL1730131T3 (pl)	2012-10-31	Glukopiranozylo-podstawione pochodne benzenu, środki lecznicze zawierające te związki, ich zastosowanie i sposób ich wytwarzania
CL2009000173A1 (es)	2010-02-12	Compuestos derivados de urea-tetrahidroxiquinoxalina; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento y la prevencion de la obesidad y la diabetes, resistencia a la insulina, sindrome metabolico, entre otros.
CL2007002610A1 (es)	2008-02-01	Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2008002227A1 (es)	2009-04-17	Compuestos derivados de 4-[(8r)-4-amino-5-oxo-7,8-dihidrorimido[5,4-f][1,4]oxazepin-6(5h)-il]fenilo sustituido; su composicion farmaceutica; y uso de los compuestos en el tratamiento de la diabetes de tipo 2, utiles particularmente para tratar la obesidad.
CL2004000827A1 (es)	2005-03-04	Compuestos derivados de 1,2-diazoles o 1,3-diazoles condensados con un heterociclo, composicion farmaceutica; y uso para tratar enfermedades moduladas por antagonistas de receptores canabinoides, tales como obesidad y sobrepeso.
CL2008001612A1 (es)	2009-05-15	5-(3-hidroxi-7-sustituido-naftalen-2-il)-1, 1-dioxo-[1,2,5]tiadiazolidin-3-ona; su uso para tratar un trastorno hiperproliferativo; la composicion farmaceutica que los contiene; y sus procesos de preparacion.
CL2008001125A1 (es)	2008-10-24	Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
CL2007003264A1 (es)	2008-05-16	Compuestos derivados de 1,4-benzotiepina 1,1-dioxido sustituidos con radicales bencilo; producto farmaceutico; y uso para el tratamiento de trastornos del metabolismo de lipidos, hiperlipidemia, resistencia a la insulina, diabetes y trastornos del sn
CL2008001126A1 (es)	2008-10-24	Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
CL2007002971A1 (es)	2008-05-30	Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
CL2009000035A1 (es)	2009-11-27	Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras.
ITMI20031570A1 (it)	2005-02-01	Composizione per uso dietetico, farmaceutico o cosmetico
CL2008002247A1 (es)	2009-05-29	Compuestos derivados de fenil amida; proceso de preparacion; composicion farmaceutica que los contiene; y su uso en la preparacion de medicamentos para el tratamiento de trastornos del sueno, narcolepsia y trastornos psiquiatricos, entre otros.
PT103884A (pt)	2008-05-19	Composições de libertação prolongada e métodos para a sua preparação
DE602006020273D1 (de)	2011-04-07	Substituierte heteroarylamidmodulatoren der aktivität des glucokortikoidrezeptors, von ap-1 und/oder von nfkb und anwendung davon
DE602004017463D1 (de)	2008-12-11	Diphenylpyridinderivate, deren herstellung und deren therapeutische anwendung